Climb Bio, Inc. (NASDAQ:CLYM)
| Market Cap | 601.83M+483.9% |
| Revenue (ttm) | 0 |
| Net Income | -57.62M-23.2% |
| EPS | -0.83-18.6% |
| Shares Out | 57.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 284,999 |
| Open | 10.55 |
| Previous Close | 10.71 |
| Day's Range | 10.28 - 10.63 |
| 52-Week Range | 1.64 - 18.33 |
| Beta | 0.07 |
| Analysts | Buy |
| Price Target | 27.17(+158.52%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CLYM
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CLYM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CLYM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CLYM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CLYM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CLYM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CLYM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CLYM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $18.76M |
| XBIState Street SPDR S&P Biotech ETF | $12.04M |
| IWMiShares Russell 2000 ETF | $10.42M |
| VXFVanguard Extended Market ETF | $4.14M |
| VTWOVanguard Russell 2000 ETF | $2.78M |
| SCHASchwab U.S. Small-Cap ETF | $2.21M |
Estimated from each fund’s disclosed top holdings × AUM
CLYM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CLYM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score